The AIM-HI Accelerator Fund is honored to be nominated for the 2022 Prix Galien USA Incubators, Accelerators and Equity Award.
The newest Prix Galien Award category, “Incubators, Accelerators and Equity,” acknowledges the role played by organizations in guiding the next wave of innovators, by offering a range of mentoring skills including clinical trial design expertise, legal counsel, lab space, professional development, peer-to-peer support, free access to leading advisors and economic support to advance life science innovation.
At AIM-HI, we bridge the gap between innovative, early-stage cancer research and successful development of high-impact oncology products. Our integrated approach combines essential funding with development and business expertise, leading to successful oncology companies that bring forth new biomedical discoveries that create value and benefit society.
To be nominated alongside other esteemed nominees is a testament to the hard work and dedication of our staff, founders, advisory members, directors and volunteers. We are honored to be recognized by this prestigious nomination and look forward to continuing our mission of advancing innovative cancer research through collaboration and entrepreneurship.
We would like to thank all of our supporters who have helped us reach this point, including our sponsors and donors.
